XML 116 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring, Impairment and Related Charges (Tables)
 12 Months Ended
Mar. 31, 2020
Restructuring and Related Activities [Abstract]  
Summary of details for charges recorded
Restructuring, impairment and related charges for the Company’s fiscal 2019 initiatives for the year ended March 31, 2020 consisted of the following:
 
Year Ended March 31, 2020
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
European Pharmaceutical Solutions
 
Medical-Surgical Solutions
 
Other
 
Corporate
 
Total
Severance and employee-related costs, net
$
3

 
$
1

 
$
2

 
$
1

 
$
33

 
$
40

Exit and other-related costs (1)
—

 
11

 
19

 
1

 
44

 
75

Asset impairments and accelerated depreciation
—

 
5

 
1

 
—

 
10

 
16

Total
$
3

 
$
17

 
$
22

 
$
2

 
$
87

 
$
131

(1)
Exit and other-related costs primarily include project consulting fees.
Restructuring, impairment and related charges for the Company’s fiscal 2019 initiatives for the year ended March 31, 2019 consisted of the following:
 
Year Ended March 31, 2019
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
European Pharmaceutical Solutions
 
Medical-Surgical Solutions
 
Other
 
Corporate
 
Total
Severance and employee-related costs, net
$
50

 
$
33

 
$
19

 
$
16

 
$
36

 
$
154

Exit and other-related costs (1)
7

 
3

 
20

 
57

 
57

 
144

Asset impairments and accelerated depreciation
6

 
5

 
3

 
18

 
1

 
33

Total
$
63

 
$
41

 
$
42

 
$
91

 
$
94

 
$
331

(1)
Exit and other-related costs primarily include lease and other contract exit costs associated with closures of facilities and retail pharmacy stores as well as project consulting fees.
The following table summarizes the activity related to the restructuring liabilities associated with the fiscal 2019 initiatives for the year ended March 31, 2020:
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
European Pharmaceutical Solutions
 
Medical-Surgical Solutions
 
Other
 
Corporate
 
Total
Balance, March 31, 2019 (1)
$
31

 
$
38

 
$
15

 
$
29

 
$
37

 
$
150

Restructuring charges recognized
3

 
17

 
22

 
2

 
87

 
131

Non-cash charges
—

 
(5
)
 
(1
)
 
—

 
(10
)
 
(16
)
Cash payments
(13
)
 
(26
)
 
(16
)
 
(20
)
 
(61
)
 
(136
)
Other
1

 
—

 
(2
)
 
(4
)
 
(14
)
 
(19
)
Balance, March 31, 2020 (2)
$
22

 
$
24

 
$
18

 
$
7

 
$
39

 
$
110

(1)
As of March 31, 2019, the total reserve balance was $150 million of which $117 million was recorded in other accrued liabilities and $33 million was recorded in other noncurrent liabilities.
(2)
As of March 31, 2020, the total reserve balance was $110 million of which $99 million was recorded in other accrued liabilities and $11 million was recorded in other noncurrent liabilities.